Navigation Links
ISTO Technologies to Present at OneMedPlace Emerging Company Finance Conference
Date:1/6/2009

ST. LOUIS, Jan. 6 /PRNewswire/ -- ISTO Technologies, Inc. announced today that it will participate in the 2nd Annual OneMedPlace Emerging Company Finance Conference in San Francisco, CA from January 13-14, 2009. Mitchell Seyedin, Ph. D., President and CEO of ISTO, will present on Tuesday, January 13th at 10:15 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St. The conference will bring together promising emerging healthcare and life science companies with strategic and venture investors focused on new technologies, emerging and micro cap public companies. Information about OneMedPlace and the conference may be found at http://www.onemedplace.com.

ISTO is a privately-held orthobiologics company based in St. Louis, MO. The Company's discrete cell-based and biomaterial platforms encompass a number of technological breakthroughs that are poised to advance the practice of medicine by offering solutions for unmet and/or largely unsatisfied clinical needs in large orthopedic markets. ISTO's mix of clinical stage, development stage and marketed products includes DeNovo(R) ET, engineered cartilage to repair and restore joint function in the knee, NuQu(TM), a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc and InQu(R), an osteobiologic bone graft Substitute and extender.

About ISTO

ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at http://www.istotech.com or contact Scott Gill, Chief Financial Officer, at +1-314-995-6049.


'/>"/>
SOURCE ISTO Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
2. BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative
3. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
6. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
7. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
8. Life Science Alley: R&D Makes German Medical Technologies Top in Europe
9. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
10. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
11. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... WALTHAM, Mass., Nov. 2, 2010 Repligen Corporation (Nasdaq: ... second quarter of fiscal year 2011, ended September 30, ... compared to total revenue of $5,421,000 for the second ... or 35%.  Bioprocessing product revenue for the second quarter ...
... Inc. (OTC Bulletin Board: WDST ), a ... therapies to restore the health of damaged tissues and ... newest advancements in regenerative medicine on November 9th, 2010 ... role in the commercialization of the therapeutic candidate, PermaDerm™, ...
... of a Nobel prize this year but research led ... Warwick has found molecular hooks on the surface of ... provide massive benefits to researchers using transmission electron microscopes. ... mechanisms. The research team, which includes Drs. Jeremy Sloan, ...
Cached Biology Technology:Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine 2Pivoting hooks of graphene's chemical cousin could revolutionize work of electron microscopes 2
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... in their blood are more likely to survive the disease, ... of vitamin D have half the risk of dying compared ... The study is the first to correlate total blood levels ... which includes that produced after exposure to sunlight and ... survival prospects. , The University of Edinburgh team tested ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
Breaking Biology News(10 mins):The impact of big data on health care: Health Affairs' July issue 2
... of great whales ever recorded? To answer that ... the Wildlife Conservation Society have joined experts from other ... Commission on the Patagonian coast of Argentina to try ... issue is the long-term conservation of the southern right ...
... "Four and 20 black birds baked in a pie" but ... analysis, means scientists now know there is one more species of ... thought. And if Dr. Gary Voelker has his way, he,ll soon ... deforestation now occurring across its native habitat. The bird ...
... resistance to sea lice treatments such as the pyrethroids ... Pyrethroid use still increased from 2008 to 2009, although ... are being used again due to resistance problems, e.g. ... been used since 1997, was also used again in ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3African bird discovery proves there is something new under the sun 2
Request Info...
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
Request Info...
... E. coli containing a clone of the human ... Topoisomerase II alters the topological state of nucleic ... a transient break which generates a separate DNA ... double-stranded DNA passage mechanism, the enzyme can relax ...
Biology Products: